share_log

JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $25

Moomoo 24/7 ·  Mar 25 09:19

JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and lowers the price target from $29 to $25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment